comparing the effects of nicotinic acid and carbonate lanthanum on hyperphosphatemia in the hemodialysis patients: a double-blind clinical trial

background: control of the phosphorus in hemodialysis patients is very important and can be done in many ways. the purpose of the study was to compare the effects of nicotinic acid and lanthanum carbonate on hyperphosphatemia in the hemodialysis patients. materials and methods: this double-blind randomized clinical trial was done in imam hossein hospital (shahroud, iran) in 2014. the participants (n=60) were divided into two groups: control (lanthanum carbonate) and intervention group (nicotinic acid). the tapering doses of nicotinic acid and lanthanum carbonate were completed monthly in three steps from 200 to 600 mg and from 250 to 750 mg, respectively. serum phosphorus and calcium were measured in both groups and the results were compared using the paired t-test and anova. results: the comparison of mean for age in intervention (51.5±21.3 years) and control groups (50.7±22.5 years) showed no significant differences. comparing the phosphors level before the intervention in intervention (6.67±1.37 mg/dl) and control group (6.69±0.28 mg/dl) showed no significant difference. nicotinic acid significantly decreased the blood phosphorus level (p<0.001) in a dose-dependent manner. conclusion: similar to lanthanum carbonate, nicotinic acid can decrease the serum phosphorous level. however, for determining the most effective dose of the nicotinic acid, more studies are required.